Labeling for a Medtronic pacing lead, already indicated for stimulation of the His bundle, has been expanded to include the left bundle branch (LBB), the company announced today. The US Food and Drug ...

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates Medtronic is the first and only ...

GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded ...

Medtronic got an FDA approval for its OmniaSecure defibrillation lead, opening up its use in the heart’s left bundle branch, while Biotronik touted the commercial rollout of its Solia CSP S lead.

According to Medtronic, this type of procedure aims to avoid the complications that can sometimes come with traditional pacemaker placements by more closely mimicking the movements of the body. (Rasi ...

Multicenter randomized trial (n=200) assigned LBBP versus BiVP for CRT in LBBB with LVEF ≤35%, using time to death or HF hospitalization as primary endpoint. Event rates favored LBBP, reducing death ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...

Please provide your email address to receive an email when new articles are posted on . A bipolar conduction system pacing implantable cardioverter defibrillator lead met safety and effectiveness ...